Cargando…

An HIV-infected Patient with No Serious Adverse Events after Overdosing on Raltegravir

Patients with HIV infection represent a high-risk group for medication overdose because of the high frequency of complicating psychiatric disorders. Raltegravir is well-known for its low frequency of adverse effects. We herein report a 42-year-old Japanese man with HIV infection who was hospitalized...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hosoda, Tomohiro, Uehara, Yuki, Naito, Toshio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008059/ https://www.ncbi.nlm.nih.gov/pubmed/31534087 http://dx.doi.org/10.2169/internalmedicine.3498-19

Ejemplares similares

Were Additional Treatments Affecting Pharmacokinetics Administered after Raltegravir Overdosing?: Authors' Reply
por: Hosoda, Tomohiro, et al.
Publicado: (2020)

Adverse events of raltegravir and dolutegravir
por: Elzi, Luigia, et al.
Publicado: (2017)

Were Additional Treatments Affecting the Pharmacokinetics Administered after Raltegravir Overdosing?
por: Fukuchi, Takahiko, et al.
Publicado: (2020)

Bradyarrhythmia due to mirtazapine overdose: A case of serious adverse event in a suicidal patient
por: Kaya, Filiz Baloglu, et al.
Publicado: (2020)

Raltegravir in the management of HIV-infected patients
por: Stellbrink, Hans-Jürgen
Publicado: (2009)

HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009)

Role of raltegravir in the management of HIV-1 infection
por: Okeke, N Lance, et al.
Publicado: (2011)

Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients
por: Riccardi, Niccolò, et al.
Publicado: (2019)

Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection
por: Yilmaz, Aylin, et al.
Publicado: (2009)

Serious adverse event: late neurotropic disease associated with yellow fever vaccine
por: de Oliveira, Henrique Souza Barros, et al.
Publicado: (2020)

Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition
por: Naqash, Abdul Rafeh, et al.
Publicado: (2019)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events
por: Zhao, Bin, et al.
Publicado: (2018)

Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
por: Chirch, Lisa M, et al.
Publicado: (2010)

Raltegravir: The evidence of its therapeutic value in HIV-1 infection
por: Ramkumar, Kavya, et al.
Publicado: (2010)

Long-term efficacy and safety of raltegravir in the management of HIV infection
por: Liedtke, Michelle D, et al.
Publicado: (2014)

Infective endocarditis and Sjögren’s syndrome diagnosed simultaneously
por: Morita, Fujiko, et al.
Publicado: (2016)

Serious Neurological Adverse Events of Ceftriaxone
por: Lacroix, Clémence, et al.
Publicado: (2021)

A patient with psittacosis from a pigeon: A reminder of the importance of detailed interviews and relative bradycardia
por: Fukui, Sayato, et al.
Publicado: (2021)

Antiretroviral Therapy Containing Raltegravir to Prevent Mother-to-Child Transmission of HIV in Infected Pregnant Women
por: Cecchini, Diego M., et al.
Publicado: (2017)

Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure
por: Jacobs, Tom G., et al.
Publicado: (2022)

Raltegravir: first in class HIV integrase inhibitor
por: Temesgen, Zelalem, et al.
Publicado: (2008)

A serious adverse surgical event: Management of suspected HSV-1 keratitis in a donor cornea
por: Kaye, Rebecca, et al.
Publicado: (2017)

Post lumbar puncture headache: Case report of a serious adverse event in first-in-human study
por: Shin, Wonsuk, et al.
Publicado: (2017)

Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy
por: Charpentier, Charlotte, et al.
Publicado: (2010)

Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics
por: Larson, Kajal B, et al.
Publicado: (2013)

Raltegravir monohydrate
por: Yamuna, Thammarse S., et al.
Publicado: (2013)

Undetectable proviral DNA and viral RNA levels after raltegravir administration in two cats with natural feline leukemia virus infection
por: Santos, Carla Regina Gomes Rodrigues, et al.
Publicado: (2022)

HOW TO TREAT PATIENTS AFTER SERIOUS ADVERSE EFFECTS CAUSED BY TNF INHIBITORS?
por: Sršen, Saša, et al.
Publicado: (2020)

Identification of serious, unpredictable adverse events with tocilizumab
Publicado: (2020)

A case of infective endocarditis along with a ruptured valve caused by Streptococcus agalactiae in an immunocompetent man
por: Suzuki, Kiyozumi, et al.
Publicado: (2016)

Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir
por: Bercoff, Danielle Perez, et al.
Publicado: (2010)

Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification
por: Ananworanich, Jintanat, et al.
Publicado: (2015)

Steven-Johnson Syndrome: A Rare but Serious Adverse Event of Nivolumab Use in a Patient With Metastatic Gastric Adenocarcinoma
por: Saad, Eltaib, et al.
Publicado: (2022)

The suspected unexpected and serious adverse events of antiretroviral drugs used as HIV prophylaxis in HIV uninfected persons
por: Pietraszkiewicz, Ewa, et al.
Publicado: (2014)

Influence of smoking on HIV infection among HIV-infected Japanese men
por: Oka, Fukuko, et al.
Publicado: (2012)

Serious adverse events associated with yellow fever vaccine
por: de Menezes Martins, Reinaldo, et al.
Publicado: (2015)

Analysis of serious adverse event: Writing a narrative
por: Nambiar, Indu
Publicado: (2018)

ADVERSE EVENTS AFTER ZOLPIDEM INTAKE
por: Thara, R.
Publicado: (2001)

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
por: Zhao, Bin, et al.
Publicado: (2019)

Use of once-daily raltegravir-based HAART in HIV-infected injection drug users
por: Tossonian, HK, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_pia32rjc5e67uhilvnpilcagor